InventisBio (SH:688382) 2 1 Shi Ji Jing Ji Bao Dao·2025-05-19 00:45Policy Developments - The National Health Commission will enhance investment guarantees for childcare services, aiming for significant improvements in service quality by the end of 2027, including better management systems and increased registration rates for childcare institutions [2] Drug and Device Approvals - Bristol-Myers Squibb's Opdivo has been approved by the European Commission for use in a perioperative treatment regimen for high-risk resectable non-small cell lung cancer (NSCLC) patients, marking it as the first PD-(L)1 inhibitor approved for this indication in the EU [4] Capital Markets - Jiuzhoutong announced a participation in establishing a 25 million yuan industry fund, with a significant contribution of 22.99 million yuan, indicating a strategic move to foster innovation in pharmaceuticals and digital healthcare [5] - AbbVie has entered a collaboration with ADARx Pharmaceuticals to develop small interfering RNA (siRNA) therapies across multiple disease areas, with an upfront payment of $335 million and potential milestone payments totaling billions [6][7] Corporate Changes - Bluefan Medical announced a change in its indirect controlling shareholder, with Langhui Petrochemical acquiring a 52.0395% stake in Bluefan Investment, although the actual controller remains unchanged [8] - ST Muyu will remove risk warnings and change its name to Tianmu Pharmaceutical starting May 20, 2025, with an increase in daily price fluctuation limits from 5% to 10% [9] Industry Events - WuXi AppTec's investee company Hanbang Technology was listed on the Shanghai Stock Exchange on May 16, 2025, with WuXi holding 6.04% of the total shares post-IPO [10] Market Sentiment - Jinhe Biology's controlling shareholder plans to reduce its stake by up to 3% of the total shares, primarily to repay pledged debts [11] - ABA-Bio has completed a reduction of its stake in Yifang Bio by 9.23 million shares, representing 1.60% of the total shares [12]